Short Interest in Enzolytics, Inc. (OTCMKTS:ENZC) Drops By 39.1%

Enzolytics, Inc. (OTCMKTS:ENZC) was the target of a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 412,513 shares, a decrease of 39.1% from the January 29th total of 677,542 shares. Based on an average daily trading volume, of 14,177,742 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 14,177,742 shares, the days-to-cover ratio is currently 0.0 days.

Enzolytics Price Performance

Shares of OTCMKTS:ENZC opened at $0.00 on Friday. Enzolytics has a 1 year low of $0.00 and a 1 year high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.